XML 26 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (35,041,673) $ (42,421,737)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Goodwill impairment 2,943,000 15,776,767 $ 41,687,871
Intangibles impairment 5,899,307  
Lease impairment 79,287  
Stock-based compensation 80,606 1,305,329  
Depreciation and amortization 1,076,081 3,811,770  
Defined benefit plan obligation and other (88,777) 93,692  
Gain on disposal of property and equipment (13,522)  
Interest added to convertible note payable 1,164,590  
Interest expense for reduction in convertible note conversion price 6,351,221  
Amortization of debt discount and warrant modification 1,116,735 612,712  
Loss on equity financing 15,305,761  
Gain on change in fair value of warrant liabilities (3,094,000)  
Loss on debt extinguishment 1,572,512 1,933,368  
Changes in assets and liabilities:      
Accounts receivable 593,038 223,457  
Inventories 1,248,186 53,178  
Prepaid expenses and other current assets 199,652 543,703  
Accounts payable (281,367) 1,105,947  
Accrued liabilities and other liabilities 185,000 44,499  
Contract liabilities (74,215) (280,685)  
Other 185,000 263,029  
Net cash used in operating activities (6,572,172) (10,956,377)  
CASH FLOW FROM INVESTING ACTIVITIES:      
Purchases of property and equipment (49,485) (215,357)  
Proceeds from the sale of property and equipment 27,510  
Capitalization of platform development costs (357,724)  
Capitalization of internal-use software costs (72,102) (203,889)  
Net cash used in investing activities (94,077) (776,970)  
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from the sale of Common Stock and warrant liabilities 5,688,239 3,967,400  
Exercise of Series B warrants 4,767,318  
Sale of Series F preferred stock 4,775,000 4,675,000  
Repayments on COVID loans (318,793) (91,856)  
Payments on convertible note (4,235,757)  
Conversion of warrants issued with Series F shares 497,701  
Other short-term loan (1,017,000)  
Legal fees incurred on financing activities (615,082)  
Net cash provided by financing activities 9,541,626 8,550,544  
Effects of foreign exchange rates on cash flows (80,405) (348,010)  
Net change in cash 2,794,972 (3,530,813)  
Cash at beginning of year 819,024 4,349,837  
Cash at end of year 3,613,996 819,024 $ 4,349,837
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:      
Interest cash paid 2,281,325  
Income taxes paid  
NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Right-of-use asset and liability 212,756  
Conversion of Preferred Stock, Series F Convertible to Common Stock 201 27,805  
Dividends on Series F Preferred Stock 234,439 339,631  
Deemed dividend on Series F Preferred stock and warrant 17,756,454 11,607,910  
Principal on convertible note converted to common stock 100,000  
Alternate cashless exercise of Series A Warrants $ 6,309